Contact

Our portfolio

Primagen

Primagen Holding focuses on developing molecular diagnostic tests and investing in bio- and medtech startups. The company generates revenues through the licensing of their diagnostics technology. Primagen Holding’s portfolio includes investments in PulseCath and Akkolens International.

  • Institute: Amsterdam UMC
Industry: Diagnostics, Infectious Disease
  • Founding year: 1993
Visit website

Want to get in contact about Primagen?

We’re happy to connect. Reach out to our investment manager working with the team to learn more or explore potential opportunities.

Browse all investment managers

Marc Roelofs

Life Science & Health

Our portfolio

Check out similar ventures

Rsouth Antibodies
Developing therapeutic antibodies, including the blockbuster RSV drug Nirsevimab.
AMI Pharma
Advancing new therapeutics for Type 1 Diabetes and autoimmune diseases.
Parkinnova Therapeutics
Developing novel treatments for Parkinson’s disease and dopamine disorders.
AlpENa Biosciences
Developing bispecific antibodies as enhanced cancer immunotherapy.
Rsouth Antibodies
Developing therapeutic antibodies, including the blockbuster RSV drug Nirsevimab.
AMI Pharma
Advancing new therapeutics for Type 1 Diabetes and autoimmune diseases.
Parkinnova Therapeutics
Developing novel treatments for Parkinson’s disease and dopamine disorders.
AlpENa Biosciences
Developing bispecific antibodies as enhanced cancer immunotherapy.
Explore full AAV portfolio
Contact